geh300079
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Mar 31, 2026 (NCT07219238)
Timeline
2020s
- Jan 1, 2026
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- DNA topoisomerase II alphaINHIBITOR
TOP2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07219238 | Phase 2/Phase 3 (Phase 3) | Mar 31, 2026 | Fortrea, General Electric |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fortrea | For profit | 1 | 0 | 1 | 2026 |
| General Electric | For profit | 1 | 1 | 1 | 2026 |
2 organizations
Page 1 / 1